[难以治疗,透的克罗恩病的治疗挑战 - 多学科方法]
Bernadett Farkas1, Péter Bacsur1, Emese Ivány1
11 Szegedi Tudományegyetem, Szent-Györgyi Albert Orvostudományi Kar, Klinikai Központ, Belgyógyászati Klinika, Gasztroenterológiai Centrum Szeged, Kálvária sgt. 57., 6725 Magyarország.
在其他疗法失败后,Upadacitinib是一种JAK1抑制剂,有效地治疗了一名年轻女性的严重透性克罗恩病和直阴道. 这种治疗导致了囊的关闭和完整的结肠愈合.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 垂直阴道抽是穿透克罗恩病的一种罕见并发症.
- 标准治疗包括药物治疗和手术,但对直阴腺的疗效有限.
- 较新的生物制剂和小分子剂显示出潜力,但在透克罗恩病方面数据有限.
研究的目的:
- 报告帕达西提尼布在患有耐火性穿透性克罗恩病和直阴管的患者中的有效性.
- 评估upadacitinib作为重症复杂克罗恩病的第五线疗法.
主要方法:
- 一名年轻妇女的病例报告,患有中度至重度的穿透性克罗恩病和复发性直阴道.
- 患者之前接受过多次生物治疗.
- 治疗包括偏离性静脉静脉切除术和开启upadacitinib (选择性JAK1抑制剂) 作为第五线治疗.
主要成果:
- 经过12周的诱导期与upadacitinib,观察到完全关闭的直阴道.
- 还检测到了整个结肠的完整粘膜愈合.
- 患者在疾病活动中经历了显著的改善.
结论:
- 在一个难以治疗的穿透性克罗恩病病例中,乌帕达西替尼 (upadacitinib) 显示出有效性,这种病例具有中度至重度的光活动和复发性直阴道.
- 选择性JAK1抑制可能是耐火病例的可行选择.
- 需要进一步的研究来证实这些发现在更大的患者队列中.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
